Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-anilino-6-cyclohexylmethoxypurine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
A synthetic small molecule belonging to the hypoxanthine class of purines, characterized by a cyclohexylmethoxy group at the purine C6 position and an anilino (phenylamino) group at C2. It acts as an ATP competitive inhibitor of cyclin-dependent kinase 2 (CDK2), a key regulator of cell cycle progression. The compound has been studied primarily in preclinical settings as a tool compound for probing CDK function and selectivity, but it is not approved for clinical use and has no known therapeutic indications[1][8]. Its mechanism involves binding to the ATP site of CDK2, thereby inhibiting its kinase activity.
- Other names
- 2-anilino-6-cyclohexylmethoxypurine444722-80-96-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amineDTXSID30274313DTXSID-30274313DTXSID 30274313DTXCID20225793DTXCID-20225793DTXCID 20225793SCHEMBL6791643SCHEMBL-6791643SCHEMBL 6791643XWWRLKIBRPJQJX-UHFFFAOYSA-NO6-Cyclohexylmethylguanine deriv. 2O-6-Cyclohexylmethylguanine deriv. 2O 6-Cyclohexylmethylguanine deriv. 2DB06948DB-06948DB 069486-(cyclohexylmethoxy)-N-phenyI -9H-purin -2 -amine
02
Targets
CDK2 (Cyclin-dependent kinase 2)CDK1 (Cyclin-dependent kinase 1)
Beyond the preview
Go deeper on 2-anilino-6-cyclohexylmethoxypurine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-anilino-6-cyclohexylmethoxypurine.